Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-003 (ambrisentan) in decompensated cirrhosis with recurrent ascites
2018-002088-25Phase 2Terminated
- Sponsor
- Noorik Biopharmaceuticals AG
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ambrisentan in Cirrhosis, sponsored by Noorik Biopharmaceuticals AG. Primary endpoint: Change in hepatic vein pressure gradient (HVPG). Started Nov 2018; status: terminated.
02
Drugs
ambrisentan
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2018-002088-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002088-25.